The future of renoprotection: Frustration and promises

Slides:

Advertisements

Similar presentations

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Renoprotective Effect of Renin-Angiotensin-Aldosterone.

Advertisements

Management of IgA nephropathy: Evidence-based recommendations

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.

Isolated Systolic Hypertension: An Update After SPRINT

Volume 84, Issue 2, Pages (August 2013)

Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction

Diabetic Kidney Disease: An ACEI (or an ARB) in the Hole

Improving Transitions in CKD: Failure Mode

Viper venom for diabetic nephropathy

Frederic Rahbari-Oskoui, MD, MS American Journal of Kidney Diseases

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

Thinking Beyond New Clinical Guidelines: Update in Hypertension

Step Care Therapy for Hypertension in Diabetic Patients

Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani

Membranous nephropathy: When and how to treat

Viper venom for diabetic nephropathy

Correction to Lancet Diabetes Endocrinol 2015; 3: 263–74

Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus George L. Bakris, MD Mayo Clinic.

Renoprotective effects of vitamin D analogs

Propofol as a panacea for acute kidney injury?

Volume 81, Issue 7, Pages (April 2012)

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Volume 63, Issue 3, Pages (March 2003)

Volume 80, Issue 9, Pages (November 2011)

Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016 Murray Epstein, MD, Daniel A. Duprez,

Volume 94, Issue 3, Pages (September 2018)

Correction to Lancet Diabetes Endocrinol 2015; 3: 263–74

Steven J. Rosansky, Richard J. Glassock Kidney International

Volume 70, Issue 11, Pages (December 2006)

Volume 72, Issue 12, Pages (December 2007)

Volume 55, Issue 3, Pages (March 1999)

Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension A. Davenport, C. Cox, R. Thuraisingham Kidney.

Volume 71, Issue 11, Pages (June 2007)

Saulo Klahr, Jeremiah J. Morrissey Kidney International

Osteopontin in diabetic nephropathy: signpost or road?

Volume 69, Issue 12, Pages (June 2006)

Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Areef Ishani, Charles A. Herzog,

David M. Charytan, John P. Forman Kidney International

Special deLIVERy: podocyte injury promotes renal angiotensin II generation from liver- derived angiotensinogen David I. Ortiz-Melo, Robert F. Spurney

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Calcium sensing in podocytes

Volume 87, Issue 1, Pages (January 2015)

Volume 84, Issue 5, Pages (November 2013)

The global challenge of chronic kidney disease

Isolated Systolic Hypertension: An Update After SPRINT

Comparative Superiority of ACE Inhibitors Over Angiotensin Receptor Blockers for People With CKD: Does It Matter? Dimitris Mavridis, PhD American Journal.

Mediterranean diets: are they practical in the Western world?

Volume 81, Issue 7, Pages (April 2012)

Carmine Zoccali, Francesca Mallamaci Kidney International

Volume 73, Issue 5, Pages (March 2008)

Renin–angiotensin system blockade and diabetes: moving the adipose organ from the periphery to the center Oliver Lenz, Alessia Fornoni Kidney International

KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline

Volume 56, Pages S28-S30 (July 1999)

Volume 68, Pages S87-S94 (August 2005)

Volume 64, Issue 4, Pages (October 2003)

Juan Jesús Carrero, PhD American Journal of Kidney Diseases

The future of renoprotection

Kathryn J. Wiggins, Darren J. Kelly Kidney International

Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti

Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications

Volume 81, Issue 11, Pages (June 2012)

Unadjusted odds ratio of death at 6 mo for medications (β blockers [BBL], angiotensin-converting enzyme inhibitors [ACEI]/angiotensin receptor blockers.

Volume 57, Issue 2, Pages (October 2000)

Volume 75, Issue 8, Pages (April 2009)

Combination angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) reduced risk for renal end point versus ACEI or ARB. Effect.

An updated general approach for achieving BP goals in people with diabetes. An updated general approach for achieving BP goals in people with diabetes.

Proteinuria and hypertension with tyrosine kinase inhibitors

Renoprotection with vitamin D: Specific for diabetic nephropathy?

Presentation transcript:

The future of renoprotection: Frustration and promises Arrigo Schieppati, Giuseppe Remuzzi Kidney International Volume 64, Issue 6, Pages 1947-1955 (December 2003) DOI: 10.1046/j.1523-1755.2003.00340.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Schematic representation of podocyte disfunction caused by protein overload in chronic nephropathies. Abbreviations are: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blockers; TGF-β, transforming growth factor-β. Kidney International 2003 64, 1947-1955DOI: (10.1046/j.1523-1755.2003.00340.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 Algorithm of the remission clinic for chronic nephropathies. In the box the targets for remission clinic are reported. Abbreviations are: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blockers. CCB, calcium channel blockers; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein; HbA1c, hemoglobin A1c. Kidney International 2003 64, 1947-1955DOI: (10.1046/j.1523-1755.2003.00340.x) Copyright © 2003 International Society of Nephrology Terms and Conditions